Zai Lab (Shanghai) Co., Ltd.
Clinical trials sponsored by Zai Lab (Shanghai) Co., Ltd., explained in plain language.
A commercial-stage biopharmaceutical company developing and commercializing medicines.
Not investment advice. Company information is shown for context only. Clinical trials frequently fail.
Advertising disclosure. Links marked "(ad)" go to partners we have a commercial relationship with, either a broker where you can trade or a stock-research service, and we may earn a commission if you open an account or subscribe. This never affects what is shown here.
Upcoming readouts
Trials from this sponsor expected to report results within the next 12 months.
- First human test of ZL-1503 begins to uncover how the body handles it Results expected Feb 2027 (estimated)
- New hope for thyroid eye disease: phase 3 drug trial launches in china Results expected Mar 2027 (estimated)
- New drug cocktail targets tough lung cancer Results expected May 2027 (estimated)
- New drug ZL-1310 tested in patients with Hard-to-Treat cancers Results expected Aug 2027 (estimated)
- Can a new drug ease schizophrenia symptoms in daily life? Results expected Aug 2027 (estimated)
-
Can a new drug ease schizophrenia symptoms in daily life?
Disease control Not yet recruitingThis study follows 250 Chinese adults with schizophrenia who are prescribed KarXT, a combination of xanomeline and trospium chloride. Over 17 weeks, researchers observe how doctors use the drug, how well patients stick with it, and what side effects occur. The goal is to see if K…
Sponsor: Zai Lab (Shanghai) Co., Ltd. • Aim: Disease control
Last updated Sep 05, 2026 00:00 UTC
-
Can a targeted drug combo outperform standard care for aggressive lung cancer?
Disease control Not yet recruitingThis phase 3 trial tests whether the experimental drug ZL-1310, when combined with an immunotherapy drug, can help people with extensive-stage small cell lung cancer live longer than those receiving standard chemotherapy plus immunotherapy. The study enrolls about 530 adults who …
Phase 3 • Sponsor: Zai Lab (Shanghai) Co., Ltd. • Aim: Disease control
Last updated Sep 02, 2026 00:00 UTC
-
First human test of ZL-1503 begins to uncover how the body handles it
Knowledge-focused Not yet recruitingThis early-stage trial is testing a new drug called ZL-1503 in healthy volunteers. The goal is to understand how the drug moves through the body, how safe it is, and how well people tolerate it after a single injection under the skin or into a vein. The study involves 36 healthy …
Phase 1 • Sponsor: Zai Lab (Shanghai) Co., Ltd. • Aim: Knowledge-focused
Last updated Aug 22, 2026 00:00 UTC